Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy

NCT07005882 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer Patients
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
HR+/HER2- Breast Cancer
Radiation Therapy

Interventions

DRUG: Elacestrant
RADIATION: PULSAR

Sponsor

Azienda Ospedaliero-Universitaria Careggi